RNXT

SEC source: 0001493152-26-045578 · ownership.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,924

Underlying: Common Stock · 55,924 shares

Expires 2036-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

SEC source: 0001493152-26-045580 · ownership.xml · derivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,924

Underlying: Common Stock · 55,924 shares

Expires 2036-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

SEC source: 0001493152-26-045577 · ownership.xml · derivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,924

Underlying: Common Stock · 55,924 shares

Expires 2036-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

SEC source: 0001493152-26-045582 · ownership.xml · derivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,924

Underlying: Common Stock · 55,924 shares

Expires 2036-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

SEC source: 0001493152-26-042650 · ownership.xml · nonDerivative · entry 1

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,380

F1 · deemedExecutionDate: The reported transaction involved the Reporting Person's receipt of a grant of 80,000 restricted stock units ("RSUs") for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

F1 · shares: The reported transaction involved the Reporting Person's receipt of a grant of 80,000 restricted stock units ("RSUs") for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

F1 · price: The reported transaction involved the Reporting Person's receipt of a grant of 80,000 restricted stock units ("RSUs") for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

SEC source: 0001493152-26-024726 · ownership.xml · nonDerivative · entry 1

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,380

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · balance_after: A grant of 58,953 restricted stock units ("RSUs") was previously reported for the Reporting Person's future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed. As of April 30, 2026, 8,823 of such RSUs had vested, leaving a remaining balance of 50,130 unvested RSUs.

SEC source: 0001493152-26-015592 · ownership.xml · derivative · entry 1

Gentry Leesa · CIK 0002013097 · Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,550

Underlying: Common Stock · 128,550 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

F1 · derivative.expiration_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

SEC source: 0001493152-26-015594 · ownership.xml · derivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 946,107

Underlying: Common Stock · 946,107 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

F1 · derivative.expiration_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

SEC source: 0001493152-26-015591 · ownership.xml · derivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 621,727

Underlying: Common Stock · 621,727 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 621,727 shares of the Issuer's common stock (319,073 shares of which are underlying incentive stock options and 302,654 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

F1 · derivative.expiration_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 621,727 shares of the Issuer's common stock (319,073 shares of which are underlying incentive stock options and 302,654 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

SEC source: 0001493152-26-015593 · ownership.xml · nonDerivative · entry 1

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,380

F1 · deemedExecutionDate: The reported transaction involved the Reporting Person's receipts of (i) a grant of 8,777 restricted stock units ("RSUs") for his service as the Chief Financial Officer of the Issuer for February 2026, which are fully vested upon grant, and (ii) a grant of 12,270 RSUs for his service as the Chief Financial Officer for March 2026, which are fully vested upon grant and (iii) a grant of 58,953 RSUs for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

F1 · shares: The reported transaction involved the Reporting Person's receipts of (i) a grant of 8,777 restricted stock units ("RSUs") for his service as the Chief Financial Officer of the Issuer for February 2026, which are fully vested upon grant, and (ii) a grant of 12,270 RSUs for his service as the Chief Financial Officer for March 2026, which are fully vested upon grant and (iii) a grant of 58,953 RSUs for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

F1 · price: The reported transaction involved the Reporting Person's receipts of (i) a grant of 8,777 restricted stock units ("RSUs") for his service as the Chief Financial Officer of the Issuer for February 2026, which are fully vested upon grant, and (ii) a grant of 12,270 RSUs for his service as the Chief Financial Officer for March 2026, which are fully vested upon grant and (iii) a grant of 58,953 RSUs for his future service as the Chief Financial Officer of the Issuer, subject to monthly vesting with the RSUs valued based on the closing price on the last trading day of the month in which the services were performed.

SEC source: 0001493152-26-013083 · ownership.xml · nonDerivative · entry 1

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,380

F1 · shares: The reported transaction involved the Reporting Person's receipt of a grant of 12,380 restricted stock units for his service as a consultant of the Issuer for January 2026.

F1 · price: The reported transaction involved the Reporting Person's receipt of a grant of 12,380 restricted stock units for his service as a consultant of the Issuer for January 2026.

SEC source: 0001493152-26-012483 · ownership.xml · derivative · entry 2

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Laurence Marton Rollover IRA

Disclosed balance after: 4,860

Underlying: Common Stock · 4,860 shares

Expires not disclosed

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000.

F2 · derivative.exercise_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

F2 · derivative.expiration_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

SEC source: 0001493152-26-012483 · ownership.xml · nonDerivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Laurence Marton Rollover IRA

Disclosed balance after: 9,720

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000.

SEC source: 0001493152-26-012482 · ownership.xml · derivative · entry 3

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The Bagai Family Trust

Disclosed balance after: 12,150

Underlying: Common Stock · 12,150 shares

Expires not disclosed

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000.

F2 · derivative.exercise_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

F2 · derivative.expiration_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

SEC source: 0001493152-26-012482 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · The Bagai Family Trust

Disclosed balance after: 313,357

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000.

F3 · balance_after: 289,057 shares of common stock are held of record by The Bagai Family Trust and were previously reported as "directly" beneficially held by the Reporting Person.

SEC source: 0001493152-26-012481 · ownership.xml · derivative · entry 2

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Voll Family Trust DTD 6/23/2010 Mark Voll TTEE

Disclosed balance after: 48,600

Underlying: Common Stock · 48,600 shares

Expires not disclosed

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $100,000.

F2 · derivative.exercise_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

F2 · derivative.expiration_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

SEC source: 0001493152-26-012481 · ownership.xml · nonDerivative · entry 1

VOLL MARK · CIK 0001207512 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Voll Family Trust DTD 6/23/2010 Mark Voll TTEE

Disclosed balance after: 97,200

F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $100,000.

SEC source: 0001493152-26-003181 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 798,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: Reflects a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $0.995 to $1.00.

SEC source: 0001493152-26-000255 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 788,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-26-000157 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 778,665

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: Reflects a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $0.825 to $0.873.

SEC source: 0001493152-25-028650 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 340,040

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-25-028439 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,040

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-25-028057 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 778,460

F1 · shares: Reflects an open market purchase of the Issuer's securities.

SEC source: 0001493152-25-026516 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-25-024875 · ownership.xml · nonDerivative · entry 2

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 756,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-25-024875 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 744,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001493152-25-016760 · ownership.xml · derivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,640

Underlying: Common Stock · 47,640 shares

Expires 2035-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.

SEC source: 0001493152-25-016756 · ownership.xml · derivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,640

Underlying: Common Stock · 47,640 shares

Expires 2035-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.

SEC source: 0001493152-25-016758 · ownership.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,640

Underlying: Common Stock · 47,640 shares

Expires 2035-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.

SEC source: 0001493152-25-016789 · ownership.xml · derivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,640

Underlying: Common Stock · 47,640 shares

Expires 2035-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.

SEC source: 0001641172-25-025459 · ownership.xml · nonDerivative · entry 2

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,040

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-025459 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,040

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-017831 · ownership.xml · derivative · entry 1

Gentry Leesa · CIK 0002013097 · Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,619

Underlying: Common Stock · 6,619 shares

Expires not disclosed

F1 · shares: Represents an award of 2,621 incentive stock options and 3,998 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025.

F2 · derivative.exercise_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F2 · derivative.expiration_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F1 · derivative.underlying_shares: Represents an award of 2,621 incentive stock options and 3,998 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025.

SEC source: 0001641172-25-017830 · ownership.xml · derivative · entry 1

Kocak Ron · CIK 0002011160 · VP, Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,600

Underlying: Common Stock · 41,600 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F1 · derivative.expiration_date: Represents an award of 41,600 incentive stock options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

SEC source: 0001641172-25-017832 · ownership.xml · derivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,498

Underlying: Common Stock · 102,498 shares

Expires not disclosed

F1 · shares: Represents an award of 21,072 incentive stock options and 81,426 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025.

F2 · derivative.exercise_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F2 · derivative.expiration_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F1 · derivative.underlying_shares: Represents an award of 21,072 incentive stock options and 81,426 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025.

SEC source: 0001641172-25-017833 · ownership.xml · derivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,636

Underlying: Common stock · 63,636 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents an award of 63,636 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

F1 · derivative.expiration_date: Represents an award of 63,636 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035.

SEC source: 0001641172-25-014212 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 734,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001641172-25-008842 · ownership.xml · derivative · entry 2

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,480 shares

Expires 2025-10-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the reporting person's cash exercise of an outstanding stock option into shares of common stock, with no sale of such shares of common stock.

F2 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable.

SEC source: 0001641172-25-008842 · ownership.xml · nonDerivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,164

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the reporting person's cash exercise of an outstanding stock option into shares of common stock, with no sale of such shares of common stock.

SEC source: 0001641172-25-014112 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 713,460

F1 · kind: On April 22, 2025, the reporting person made a bona fide gift of an aggregate of 400,000 shares of the Issuer's common stock to trusts for the benefit of the reporting person's children. The reporting person is not a trustee or beneficiary of such trusts and therefore no longer has a beneficial ownership interest in the subject shares.

SEC source: 0001641172-25-004955 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,040

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-005139 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,113,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001641172-25-005108 · ownership.xml · derivative · entry 1

Gentry Leesa · CIK 0002013097 · Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,477

Underlying: Common Stock · 26,477 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 26,477 shares of the Issuer's common stock (7,173 shares of which are underlying incentive stock options and 19,304 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035.

F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 26,477 shares of the Issuer's common stock (7,173 shares of which are underlying incentive stock options and 19,304 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035.

SEC source: 0001641172-25-005109 · ownership.xml · derivative · entry 1

Kocak Ron · CIK 0002011160 · VP, Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,400

Underlying: Common Stock · 166,400 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted an incentive stock option to purchase up to 166,400 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035.

F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted an incentive stock option to purchase up to 166,400 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035.

SEC source: 0001641172-25-005107 · ownership.xml · derivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,992

Underlying: Common Stock · 409,992 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 409,992 shares of the Issuer's common stock (187,812 shares of which are underlying incentive stock options and 222,180 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035.

F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 409,992 shares of the Issuer's common stock (187,812 shares of which are underlying incentive stock options and 222,180 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035.

SEC source: 0001641172-25-005106 · ownership.xml · derivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,542

Underlying: Common Stock · 254,542 shares

Expires not disclosed

F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted a non-qualified stock option to purchase up to 254,542 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035..

F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted a non-qualified stock option to purchase up to 254,542 shares of the Issuer's common stock, with such option vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on April 14, 2035..

SEC source: 0001641172-25-003951 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,098,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 3

Kocak Ron · CIK 0002011160 · VP Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,595

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 2

Kocak Ron · CIK 0002011160 · VP Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,095

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-003504 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,540

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82795 to $0.829, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.